DuPont collaborates with medical experts in China to further examine the clinical efficacy of probiotics
KUNSHAN, CHINA, December 13, 2018 – Today, DuPont Nutrition & Health presented on the latest developments on clinical research, market insights and trends on global probiotics products at the 3rdProbiotics and Health Medical Science Summit. Top food safety and clinical experts in China exchanged the standards and safety of probiotics and domestic clinical research results with focus on digestion, immunity, women's & children's health, and internal microbiota regulation. The summit attracted close to 50 chief physicians from the Department of Gastroenterology, Nutrition, Dermatology, Endocrinology and Internal Medicine of leading Third-Level Grade-A hospitals across the country.
Megan DeStefano, Global Marketing Manager, Probiotics, DuPont Nutrition & Health said, “Through participating in seminars and scientific health conferences, DuPont hopes to infuse probiotics in clinical medicine and promote the wide range of benefits and applications it has in health food and pharmaceutical applications."
The rise of global clinical researches on probiotics in the areas of digestive, immune and metabolic health et cetera are redefining the importance of a healthy gut flora in the human microbiome. Probiotics are now not only limited to food and dietary supplements formats but are also applicable in the pharmaceutical industry. With more than a century of expertise in dairy cultures, DuPont is the only culture & probiotics supplier with a in-house nutrition and Health research center. Equipped with proprietary process and products, new state of the art facilities, along with strong local support in innovation, application, regulation and production, DuPont can help manufacturers produce high quality probiotics products and provide impeccable expertise to customers globally.
“DuPont is a global leader in the science, research and production of probiotics,” said Dr. Susan Jin, Ph.D., Product Line Leader, Probiotics, Cultures and Food Protection Ingredient, Asia Pacific, DuPont Nutrition & Health. “We will continue to maintain high potency, stability and efficacy of our HOWARU®probiotic products, and provide in-depth clinical research support, while continuing to work closely with relevant institutions and companies. This will all be beneficial to the Chinese consumers and contribute towards the vision of ‘Healthy China 2030’.” she added.
The Healthy China 2030 is a national political priority formally approved in late 2016 to progress the health and development of China. For more information, please go to http://en.nhfpc.gov.cn/HealthChina2030.html.
DuPont Nutrition & Health, a DowDuPont Specialty Products Division business, combines in-depth knowledge of food and nutrition with current research and expert science to deliver unmatched value to the food, beverage, pharmaceutical and dietary supplement industries. We are innovative solvers, drawing on deep consumer insights and a broad product portfolio to help our customers turn challenges into high-value business opportunities. More information is available at www.food.dupont.com.
DowDuPont Specialty Products, a division of DowDuPont (NYSE: DWDP), is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, building and construction, health and wellness, food and worker safety. DowDuPont intends to separate the Specialty Products Division, which will be called DuPont, into an independent, publicly traded company. More information can be found at www.dow-dupont.com.